For the quarter ended March 2026, Health Catalyst (HCAT Quick QuoteHCAT - Free Report) reported revenue of $70.76 million, down 10.9% over the same period last year. EPS came in at $0.02, compared to $0.01 in the year-ago quarter.

The reported revenue represents a surprise of +2.04% over the Zacks Consensus Estimate of $69.34 million. With the consensus EPS estimate being $0.01, the EPS surprise was +300%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Health Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Professional services: $21.29 million versus the three-analyst average estimate of $19.93 million. The reported number represents a year-over-year change of -23.8%.
• Revenue- Technology: $49.47 million versus $49.51 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -3.9% change.
• Adjusted Gross Profit- Professional Services: $4.14 million compared to the $3.34 million average estimate based on three analysts.
• Adjusted Gross Profit- Technology: $32.3 million versus the three-analyst average estimate of $32.74 million.

View all Key Company Metrics for Health Catalyst here>>>

Shares of Health Catalyst have returned +52.6% over the past month versus the Zacks S&P 500 composite's +9.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.